^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Acute Myelogenous Leukemia
    Drug:azacitidine (DNMT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    03/27/2020
    Excerpt:
    Azacitidine Mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:...acute myeloid leukaemia (AML) with 20 30% blasts and multi lineage dysplasia, according to World Health Organisation (WHO) classification...AML with > 30% marrow blasts according to the WHO classification.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    AML:…Therapy for relapsed/refractory disease…less aggressive therapy…hypomethylating agents (azacitidine or decitabine)